Natural killer cell reprogramming with chimeric immune receptors

Methods in Molecular Biology

Volumn 969, Issue , 2013, Pages 203-220

  Shimasaki, Noriko ^a   Campana, Dario ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acute lymphoblastic leukemia; Cell therapy; Chimeric receptors; Electroporation; Natural killer cells; Non Hodgkin lymphoma; Retroviral transduction

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN RECEPTOR;

ANIMAL; BIOSYNTHESIS; CELL ENGINEERING; CELLULAR IMMUNITY; CYTOLOGY; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; LEUKEMIA; LYMPHOMA; METABOLISM; METHODOLOGY; NATURAL KILLER CELL; PATHOLOGY; REVIEW;

ANIMALS; CELL ENGINEERING; GENE EXPRESSION; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS;

MLCS; MLOWN;

EID: 84878642671     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-260-5_13     Document Type: Article

References (47)

1. Vivier E, Raulet DH, Moretta A et al (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44-49
2. Karre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-de ficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675-678
3. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356:1795-1799
4. Delahaye NF, Rusakiewicz S, Martins I et al (2011) Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 17:700-707
5. Chiorean EG, Miller JS (2001) The biology of natural killer cells and implications for therapy of human disease. J Hematother Stem Cell Res 10:451-463
6. Ruggeri L, Capanni M, Casucci M et al (1999) Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 94:333-339
7. Ruggeri L, Capanni M, Urbani E et al (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295:2097-2100
8. Giebel S, Locatelli F, Lamparelli T et al (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102:814-819
9. Leung W, Iyengar R, Turner V et al (2004) Determinants of antileukemia effects of allogeneic NK cells. J Immunol 172:644-650
10. Leung W, Iyengar R, Triplett B et al (2005) Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 174:6540-6545
11. Caligiuri MA (2008) Human natural killer cells. Blood 112:461-469
12. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A (2011) Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 117:764-771
13. Miller JS, Soignier Y, Panoskaltsis-Mortari A et al (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 105:3051-3057
14. Rubnitz JE, Inaba H, Ribeiro RC et al (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 28:955-959
15. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, Seehra J, London L, Perussia B (1984) Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med 160:1147-1169
16. London L, Perussia B, Trinchieri G (1986) Induction of proliferation in vitro of resting human natural killer cells: IL 2 induces into cell cycle most peripheral blood NK cells, but only a minor subset of low density T cells. J Immunol 137:3845-3854
17. Lanier LL, Buck DW, Rhodes L et al (1988) Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 167:1572-1585
18. Carlens S, Gilljam M, Chambers BJ et al (2001) A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol 62:1092-1098
19. Alici E, Sutlu T, Bjorkstrand B et al (2008) Autologous antitumor activity by NK cells expanded from myeloma patients using GMPcompliant components. Blood 111:3155-3162
20. Fujisaki H, Kakuda H, Shimasaki N et al (2009) Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 69:4010-4017
21. Rabinowich H, Sedlmayr P, Herberman RB, Whiteside TL (1991) Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells. Cell Immunol 135:454-470
22. Robertson MJ, Cameron C, Lazo S, Cochran KJ, Voss SD, Ritz J (1996) Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun 15:213-226
23. Condiotti R, Zakai YB, Barak V, Nagler A (2001) Ex vivo expansion of CD56+ cytotoxic cells from human umbilical cord blood. Exp Hematol 29:104-113
24. Miller JS, Oelkers S, Verfaillie C, McGlave P (1992) Role of monocytes in the expansion of human activated natural killer cells. Blood 80:2221-2229
25. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G (1987) Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. Nat Immun Cell Growth Regul 6:171-188
26. Igarashi T, Wynberg J, Srinivasan R et al (2004) Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104:170-177
27. Harada H, Watanabe S, Saijo K, Ishiwata I, Ohno T (2004) A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells. Exp Hematol 32:614-621
28. Imai C, Iwamoto S, Campana D (2005) Genetic modi fication of primary natural killer cells overcomes inhibitory signals and induces speci fic killing of leukemic cells. Blood 106:376-383
29. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D (2009) Replicative potential of human natural killer cells. Br J Haematol 145:606-613
30. Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L (1998) NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. Cell Immunol 190:167-172
31. Carson WE, Fehniger TA, Haldar S et al (1997) A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 99:937-943
32. Cooper MA, Bush JE, Fehniger TA et al (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100:3633-3638
33. Fehniger TA, Caligiuri MA (2001) Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol 20:503-534
34. Wu J, Lanier LL (2003) Natural killer cells and cancer. Adv Cancer Res 90:127-156
35. Musso T, Calosso L, Zucca M et al (1999) Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood 93:3531-3539
36. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A (2004) Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol 173:3594-3598
37. Kobayashi H, Dubois S, Sato N et al (2005) The role of trans-cellular IL-15-presentation in the activation of NK-mediated killing, which leads to enhanced tumor immunesurveillance. Blood 105:721-727
38. Orange JS (2008) Formation and function of the lytic NK-cell immunological synapse. Nat Rev Immunol 8:713-725
39. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:3901-3909
40. Altvater B, Landmeier S, Pscherer S et al (2009) 2B4 (CD244) signaling by recombinant antigenspeci fic chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res 15:4857-4866
41. Rabinovich PM, Komarovskaya ME, Ye ZJ et al (2006) Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther 17:1027-1035
42. Rabinovich PM, Komarovskaya ME, Wrzesinski SH et al (2009) Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther 20:51-61
43. Li L, Liu LN, Feller S et al (2010) Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther 17:147-154
44. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P, Leung W, Campana D (2012) A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14:830-840
45. Lee DA, Verneris MR, Campana D (2010) Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol 651:61-77
46. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Campana D (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676-684
47. Phillips JH, Lanier LL (1985) A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K562. J Exp Med 161:1464-1482